



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/553,731-Conf. #4727
				Filing Date	October 18, 2005
				First Named Inventor	Christian Hubschwerlen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	64348(41925)

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-3,184,462	05/18/1965	Scarborough et al.	
	AB	US-5,250,544	10/05/1993	Lavielle et al.	
	AC	US-5,747,502	05/05/1998	Hanaoka et al.	
	AD	US-6,046,206	04/04/2000	Pamukcu et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	WO 96/39145 A1	12/12/1996	Rhone-Poulenc Rorer Pharmaceuticals Inc.		
	BB	WO 99/10442 A1	01/14/1999	Zeneca Limited		
	BC	WO 99/48461 A2	09/30/1999	Department of the Army		
	BD	WO 00/78748 A1	12/28/2000	Smithkline Beecham P.L.C.		
	BE	WO 01/07432 A2	02/01/2001	Smithkline Beecham P.L.C.		
	BF	WO 01/10842 A2	02/15/2001	Millennium Pharmaceuticals, Inc.		
	BG	WO 01/46150 A2	06/28/2001	Glaxo Group Limited		
	BH	WO 02/08224 A1	01/31/2002	Smithkline Beecham P.L.C.		
	BI	WO 02/40474 A2	05/23/2002	Aventis Pharma S.A.		
	BJ	WO 02/056882 A1	07/25/2002	Smithkline Beecham P.L.C.		
	BK	WO 02/072572 A1	09/19/2002	Aventis Pharma S.A.		
	BL	WO 03/064421 A1	08/07/2003	Glaxo Group Limited		
	BM	WO 03/087098 A1	10/23/2003	Smithkline Beecham P.L.C.		
	BN	WO 2004/002992 A1	01/08/2004	Glaxo Group Limited		
	BO	WO 2004/035569 A2	04/29/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie		
	BP	WO 2004/058144 A2	07/15/2004	Glaxo Group Limited		
	BQ	WO 2006/021448 A1	03/02/2006	Morphochem Aktiengesellschaft Für Kombinatorische Chemie		
	BR	JP 61200544 (w/abstract)	09/05/1986	Toyo Ink Mfg. Co.		
	BS	EP 0 042781 B1 (w/abstract)	03/06/1985	Pharmuka Laboratories		
	BT	EP 0 264 883 A2	04/27/1988	Banyu Pharmaceutical Co., Ltd.		
	BU	EP 0 486 022 B1	05/20/1992	Eisai Co., Ltd.		
	BV	EP 0 737 670 B1 (w/abstract)	10/16/1996	Adir et Compagnie		
	BW	DE 102 47 233 A1 (w/abstract)	06/17/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie		
	BX	DE 102 56 405 A1 (w/abstract)	06/17/2004	Morphochem Aktiengesellschaft Für Kombinatorische Chemie		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Rebecca Anderson</i>	Date Considered	01/21/2009
--------------------	-------------------------	-----------------	------------

596561

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RA/

PTO/SB/08A/B (09-08)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/553,731-Conf. #4727
				Filing Date	October 18, 2005
				First Named Inventor	Christian Hubschwerlen
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	64348(41925)

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Chemical Abstract – Wei t al.; "A practical procedure for multisubstituted .beta.-naphthols and their derivatives" Tetrahedron, 59(34), 2003, pp. 6621-6625.		
	CB	Chemical Abstract – Harayama et al.; "Novel synthesis of naphthobenzazepines from N-bromobenzyl naphthylamines by regioselective C-H activation utilizing the intramolecular coordination of an amine to Pd"; Synlett, (8), 2003, pp. 1141-1144.		
	CC	Chemical Abstract – Nagy et al.; "Theoretical and Experimental Study on Ion-Pair Formation and partitioning of organic Salts in Octano/Water and Dichloromethane/Water Systems"; Journal of the America Chemical Society; 122 (28), 2000, pp. 6583-6593.		
	CD	Chemical Abstract – Moehle et al.; "1,2,3,4-Tetrahydroquinolines as substrates for Mannich compounds"; Zeitschrift Fuer Naturforschung, B: Chemical Sciences; 53(7), 1998, pp. 742-752.		
	CE	Chemical Abstract – Mathe-Allainmat et al.; "Synthesis of 2-Amido-2,3-dihydro-1H-phenalene Derivatives as New Conformationally Restricted Ligands for Melanotin Receptors"; Journal of Medicinal Chemistry; 39 (16), 1996, pp. 3089-3095.		
	CF	Chemical Abstract – Iwasaki et al.; "Novel Selective PDE IV Inhibitors as Antiasthmatic Agents. Synthesis and Biological Activities of a Series of 1-Aryl-2,3-bis(hydroxymethyl) naphthalene Lignans"; Journal of Medicinal Chemistry, 39(14), 1996, pp. 2696-2704.		
	CG	Chemical Abstract – Zhang et al.; "Organic reactions in chiral micelles. 7. The structural effects on the asymmetric oxidation of prochiral Sulfides in chiral micelles"; Chinese Journal of Chemistry, (1), 1990, pp. 89-96.		
	CH	Chemical Abstract – Smidkal, Jan; "Synthesis of fagoronine"; Collection of Czechoslovak Chemical Communications; 53(12), 1998, pp. 3184-3192.		
	CI	Chemical Abstract – Fleischhacker et al.; "Heterocyclic fused naphthalene systems from thebaine. 1"; Liebigs Annalen Der Chemie, (5), 1983, pp. 844-851.		
	CJ	Chemical Abstract – Budzikiewicz et al.; "Vincetene, a benzopyrrolisoquinoline alkaloid, from Cynanchum vincetoxicum (L.) Pers. (Asclepiadaceae)"; Liebigs Annalen Der Chemie (8), 1979, pp. 1212-1231.		
	CK	Chemical Abstract – Frost et al.; "Naturally occurring compounds related to phenalenone. V. Synthetic approaches to structures based on 8,9-dihydro-8,8,9-trimethylphenaleno [1,2-b] furan-7-one"; Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry; (19), 1973, pp. 3159-2169.		
	CL	Chemical Abstract – Jorgensen et al.; "Thyroxine analogs. 20. Substituted 1- and 2-naphthyl ethers of 3,5-diiodotyrosine"; Journal of Medicinal Chemistry, 14(11), 1971, pp. 1023-1026.		
	CM	Chemical Abstract – Kasturi et al.; "Reactions of tetrahalo-1,2-benzoquinones. III. Reaction of tetrachloro-1,2-benzoquinone with tetralones and naphthols: pathway to the condensates"; Journal of the Chemical Society [Section] C: Organic, (9), 1970, pp. 1257-1259.		
	CN	Chemical Abstract – Harada et al.; "Structure of pristimerin, a quinonoid triterpene"; Tetrahedron Letters, 1962, pp. 603-607.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
596561 /Rebecca Anderson/	01/21/2009

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RA/